verifi® Prenatal Test
Verinata Health, Inc. is proud to offer the verifi® prenatal test — a non-invasive prenatal test that detects multiple fetal chromosomal aneuploidies using a single maternal blood draw with near-diagnostic accuracy. If you have ever wanted safer, simpler test results or wished to screen at 10 weeks instead of waiting, now you can order the verifi® prenatal test.
Increased Safety and Peace of Mind for Your Patients
Swift acceptance of the verifi® prenatal test has made a world of difference to high-risk patients across the country:
- SAFE — Routine blood draw, just one tube (7–10 ml)
- ACCURATE — Directly analyzes cell-free fetal DNA with our proprietary SAFeR™ algorithm
- EASY — Test as early as 10 weeks, no limitations in reference to patient ethnicity, BMI, ART or egg donor cases
- COMPREHENSIVE — Capable of aneuploidy detection across the genome
The basic verifi® test detects:
- T21 (Down syndrome)
- T18 (Edwards syndrome)
- T13 (Patau syndrome)
Now a wider option is available for sex chromosomes at no extra charge:
- Monosomy X (MX, Turner syndrome)
- XXX (Trisomy X)
- XXY (Klinefelter syndrome)
- XYY (Jacob’s syndrome)
- Fetal sex (XX or XY) – aids in stratifying the risk for X-linked disorders such as hemophilia, Duchenne muscular dystrophy or cases of ambiguous genitalia, such as congenital adrenal hyperplasia
As sequencing technology rapidly evolves, our research team has analyzed and implemented several changes to the testing procedure that yield enhanced test performance.
The verifi® test now includes an option for the most common sex aneuploidies, providing information previously known only through invasive results.
Sex chromosome mosaicism cannot be distinguished by this method (the occurrence of which is <0.3%). Patients with such mosaicism will have a sex chromosome result reported and will fall into one of the six categories (Monosomy X, XXX, XXY, XYY, XX, XY).
*Test performance data on file.
For patients at 10+ weeks gestation with singleton pregnancies who meet any of the following criteria:
- Advanced maternal age
- Positive results of prenatal aneuploidy screening
- Presence of ultrasound abnormalities
- Previous affected pregnancy for fetal aneuploidy